CellPoint

CellPoint enables clinicians to treat hematological malignancies by retargeting patient immune cells at the point-of-care. In 2022, CellPoint was acquired by Galapagos, a fully integrated biotechnology company. Since then, they have been united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life. As a result, we will be sharing all company updates, news, and insights on the Galapagos’ page as of now. Please follow Galapagos to stay updated on our latest developments and join our vibrant community. This page will stay online for cv referencing and historic purposes but will not be used to communicate updates. For details on the acquisition, please read our press release from 22 June 2022: https://www.glpg.com/press-release/3637/galapagos-to-acquire-cellpoint-and-aboundbio-to-accelerate-access-to-next-generation-cell-therapies